12:00 AM
 | 
Oct 07, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Vectibix panitumumab: Additional Phase III data

Additional data from the open-label, international Phase III ASPECCT trial in 999 patients with wild-type K-Ras chemorefractory mCRC showed that 6 mg/kg IV Vectibix every 14 days led to a median OS of 10.4 months vs. 10 months for IV Erbitux cetuximab every 7 days (p=0.0007 for non-inferiority). Amgen previously reported that Vectibix met the primary endpoint...

Read the full 282 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >